Who Paid My Doc
Robert Przybylski
Pediatric Cardiology Fairfax, VA Medical Doctor
NPI 1407274871 CMS profile 3518859
8260 Willow Oaks Corporate Dr Ste 400, Fairfax, VA 22031
General payments
$26,863
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Robert Przybylski of Fairfax, VA is reported in the CMS Open Payments database as having received $26,863 across 40 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 95th percentile of Pediatric Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,614 | 12 | |
| 2024 | General | $262 | 4 | |
| 2023 | General | $2,541 | 17 | |
| 2022 | General | $1,179 | 4 | |
| 2021 | General | $20,267 | 3 |
Beside peers
- Robert Przybylski
- Pediatric Cardiology median
- Middle half of Pediatric Cardiology
- National median
In program year 2025, general payments to Robert Przybylski were reported at $2,614. Among 1,168 Pediatric Cardiology profiles paid that year, the median was $146 and the middle half received between $47 and $670.
Show as a table
| Year | Robert Przybylski | Pediatric Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $124 | $35–$516 | $163 |
| 2020 | $0 | $70 | $23–$326 | $114 |
| 2021 | $20,267 | $112 | $27–$445 | $132 |
| 2022 | $1,179 | $129 | $36–$680 | $149 |
| 2023 | $2,541 | $149 | $38–$826 | $160 |
| 2024 | $262 | $131 | $37–$652 | $164 |
| 2025 | $2,614 | $146 | $47–$670 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$2,266
Medicare patients
13
Services billed
46
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Cancer | 0% | |
| Alzheimer's or dementia | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
40 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Cardiology in Virginia
Michael Vance
Pediatric Cardiology · Norfolk, VA
Michael Shorofsky
Pediatric Cardiology · Charlottesville, VA
Michael McCulloch
Pediatric Cardiology · Charlottesville, VA
Samuel Casella
Pediatric Cardiology · Richmond, VA
Firezer Haregu
Pediatric Cardiology · Roanoke, VA
John Reed
Pediatric Cardiology · Norfolk, VA
Related records
Pediatric Cardiology in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.